Key result
Tirofiban combined with dual antiplatelet therapy reduced NIHSS scores at 90 days compared to dual antiplatelet therapy alone in patients with acute ischemic stroke.
Why the study?
The study was conducted to evaluate the safety and efficacy of tirofiban in the treatment of acute ischemic stroke.
Does tirofiban combined with dual antiplatelet therapy improve neurological deficits and functional outcomes in acute ischemic stroke patients beyond the standard time window?
Cohort (n=152)
No
Does tirofiban combined with dual antiplatelet therapy improve neurological deficits and functional outcomes in acute ischemic stroke patients beyond the standard time window?
Tirofiban combined with dual antiplatelet therapy significantly improves neurological deficits and functional outcomes in acute ischemic stroke patients beyond the standard time window without increasing bleeding or mortality risks.
Answers are grounded in this paper and cite their sources.
Tirofiban addition may be considered in small vessel AIS without reperfusion; hypothesis-generating and should not yet change practice.
To evaluate the safety and efficacy of tirofiban in the treatment of acute ischemic stroke (AIS). Clinical data of 152 AIS patients with small vessel occlusion admitted in 2023 were retrospectively analyzed. These patients did not receive intravenous thrombolysis and endovascular treatment within 72 h of onset. Patients were divided into two groups (n = 76 each group): a dual antiplatelet group (aspirin + clopidogrel for 14 days, followed by aspirin alone) and a tirofiban group (dual antiplatelet therapy plus tirofiban). Neurological deficits and functional outcomes were assessed before treatment, on day 7, and day 90. Serum hs-CRP and IL-6 levels were measured prior to treatment and on day 7. Symptom aggravation, symptomatic bleeding, and mortality within 90 days were also recorded. Baseline characteristics of the two groups were comparable. Tirofiban treatment significantly improved mRS scores from baseline to day 7 (t = 5.94, p < 0.001) and day 90 (t = 5.67, p < 0.001) (F = 53.13, p < 0.001), with improvements persisting after adjusting for baseline scores (F = 32.56, p < 0.001). Moreover, tirofiban treatment significantly reduced NIHSS scores at days 7 (mean difference = - 0.97 (95% CI: - 1.53, - 0.41); t = 3.57, p < 0.001) and 90 (mean difference = - 0.82 (95% CI: - 1.29, - 0.34); t = 3.97, p < 0.001) and increased Barthel Index scores at days 7 (mean difference = 9.8 (95% CI: 4.3, 15.3); t = - 3.14, p = 0.002) and 90 (mean difference = 11.7 (95% CI: 6.2, 17.2); t = - 4.41, p < 0.001), indicating greater functional independence. No significant differences were observed between the two groups in inflammatory markers (hs-CRP and IL-6), intracranial hemorrhage, or mortality. However, there was a trend toward a higher rate of deterioration in the dual antiplatelet group (13.4% vs. 5.6%). Tirofiban combined with conventional treatment significantly improves neurological deficits and disease outcomes in AIS patients without increasing the risk of bleeding and mortality.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) conducted a cohort in Acute ischemic stroke (n=152). Tirofiban vs. Dual antiplatelet therapy (aspirin + clopidogrel) was evaluated on NIHSS score at day 90 (MD -0.82, 95% CI -1.29, -0.34, p=<0.001). Tirofiban combined with dual antiplatelet therapy reduced NIHSS scores at 90 days compared to dual antiplatelet therapy alone in patients with acute ischemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: